Samtheo Biopharma Forms Subsidiary Lyndor Bioscience to Develop Moffitt Cancer Center Rx
March 18, 2009
Samtheo Biopharma Forms Subsidiary Lyndor Bioscience to Develop Moffitt Cancer Center Rx
Samtheo formed Lyndor to further develop a small molecule licensed from Moffitt to treat chemo- and radiation-resistant cancer patients. Lyndor and Moffitt will continue to co-develop the treatment with the hopes of signing on a larger pharmaceutical partner.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Having Buoyed Healthcare Products and Services, MI Growth Group Eyes Med-Devices Incubator
March 9, 2009 / - Around the Regions
May 1, 2009 / - Expression Pathology Nabs $6.5M Investment from Abraxis to Develop Cancer Drug-Response Dxs
April 23, 2009 / ProteoMonitor - BioRegion Real Estate
March 23, 2009 / - News Scan
March 20, 2009 /